Palisade Bio - Stock Price History | PALI

Historical daily share price chart and data for Palisade Bio since 2021 adjusted for splits. The latest closing stock price for Palisade Bio as of September 27, 2021 is 2.45.
  • The all-time high Palisade Bio stock closing price was 7270.33 on April 09, 2014.
  • The Palisade Bio 52-week high stock price is 16.02, which is 553.9% above the current share price.
  • The Palisade Bio 52-week low stock price is 1.66, which is 32.2% below the current share price.
  • The average Palisade Bio stock price for the last 52 weeks is 5.45.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Palisade Bio Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 4.7002 6.5987 9.5981 3.1674 5.2789 -11.11%
2019 32.5171 39.5561 78.5003 4.5351 5.9388 -84.19%
2018 153.7286 243.5513 256.7487 37.5645 37.5645 -81.80%
2017 385.7985 485.2085 759.4481 112.5135 206.3587 -51.62%
2016 718.6921 1606.9608 1684.9686 311.2511 426.5467 -73.46%
2015 2982.8699 4384.0387 5975.3979 1575.7577 1606.9608 -62.13%
2014 5381.4242 4930.0933 7270.3275 3697.5700 4243.6246 -6.53%
2013 2681.7963 1887.7889 4586.8590 1622.5624 4540.0543 166.97%
2012 1585.0262 1560.1561 2324.6326 702.0702 1700.5702 12.95%
2011 2322.9808 3385.5388 3541.5544 1388.5389 1505.5506 -54.48%
2010 3649.1315 2886.2888 5366.9370 2808.2810 3307.5310 18.44%
2009 2062.6904 2605.4607 3245.1247 1248.1249 2792.6794 8.68%
2008 3054.3435 5710.1714 5710.1714 1684.8126 2569.5771 -55.84%
2007 4757.1063 4992.4995 6303.0307 3494.7497 5819.3823 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.032B $0.000B
Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29